Introduction c-Myc is involved in a variety of cellular functions such as proliferation, apoptosis and differentiation (Grandori et al., 2000; Baudino et al., 2002) and its translocation, amplification or deregulated expression is often associated with tumor development (Bhatia et al., 1993; Clark et al., 1994) . Its N-terminal AD is relevant for its cellular functions (Nasi et al., 2001; Baudino et al., 2002) and recruits transcription factors and coactivators (Sakamuro and Prendergast, 1999) . Via its basic helixloop-helix-leucine zipper (bHLHZip) motif, c-Myc forms a heterodimeric complex with Max. Together, they recognize a specific consensus DNA sequence, CAC(G/A)TG, called the E box (Amati et al., 1993) . Besides being an activator, via its interactions with specific proteins, such as Miz-1, c-Myc can also repress transcription (Peukert et al., 1997; Claassen and Hann, 1999) .
c-Myc promotes the elongation rather than initiation of transcription of the carbomoyl-phosphate synthase/ aspartate transcarbamoylase/dihydroorotase (cad) gene (Eberhardy and Farnham, 2001) . For these effects, its N-terminal AD binds the positive transcription elongation factor b (P-TEFb) (Eberhardy and Farnham, 2002) . P-TEFb is composed of cyclins T1, T2 or K (CycT1, CycT2, CycK) and cyclin-dependent kinase 9 (Cdk9). By phosphorylating its C-terminal domain (CTD) and other targets, it facilitates the elongation by RNA polymerase II (RNAPII) (Price, 2000) . P-TEFb is also essential for the replication of HIV (Wei et al., 1998) , several hundred genes induced by heat shock in D. melanogaster (Lis et al., 2000) , as well as effects of RelA from NF-kB (Barboric et al., 2001) , CIITA (Kanazawa et al., 2000) , androgen receptor (Lee et al., 2001) and MyoD (Simone et al., 2002) . For this reason, we investigated whether its interaction with c-Myc could have other functional consequences.
First, we examined whether a dominant-negative form of Cdk9 (DNCdk9) could interfere with the transcriptional activity of c-Myc. BOSC23 cells were transfected with the target plasmid M4 minCAT, which contains four E boxes upstream of the minimal tk promoter and the CAT reporter gene (Soucek et al., 1998) . Its CAT activity was increased fourfold when coexpressed with c-Myc (Figure 1 , lane 5). However, in the presence of increasing amounts of DNCdk9, the effects of c-Myc were inhibited in a dose-dependent manner (Figure 1 , compare lanes 6-8 to lane 5). Indeed, at highest concentrations of the inhibitor, CAT activity was reduced to almost basal levels ( Figure 1 , compare lanes 4 and 8). Of note, this concentration of DNCdk9 did not inhibit the activity of the basal tk promoter (Figure 1, lane 3) . Thus, P-TEFb is required for transcriptional effects of c-Myc.
Next, we wanted to determine if these effects were due to direct interactions between c-Myc and P-TEFb in cells. To this end, we coexpressed c-Myc first singly with the HA epitope-tagged CycT1 or Cdk9 proteins and then together with both proteins (Figure 2a) . Indeed, anti-HA antibodies revealed that anti-Myc immunoprecipitations contained both proteins (Figure 2a, lanes 1-3) . Specific coimmunoprecipitations were obtained also with the endogenous c-Myc protein (data not presented). Using GST pull-downs, we also confirmed that this interaction was direct. Since the binding between CycT1 and the AD in c-Myc had been demonstrated previously by an affinity capture assay with HeLa nuclear extracts (Eberhardy and Farnham, 2002) , we examined only different regions in CycT1. As presented in Figure 2b , the mutant CycT1 proteins from positions 1 to 611, which lack the C-terminal PEST sequence, and from 1 to 250, which contain two cyclin boxes, bound cMyc equivalently (Figure 2, lanes 2 and 3) . Importantly, the PEST sequence alone did not bind c-Myc (Figure 2 , lane 4). These cyclin boxes also bind the acidic ADs of CIITA and RelA (Kanazawa et al., 2000; Barboric et al., 2001) . We conclude that c-Myc not only requires P-TEFb for its transcriptional effects but also binds CycT1 in vivo and in vitro. Analogously to Tat, CIITA and RelA, it recruits P-TEFb to its target transcriptional units.
To confirm that the complex between c-Myc and PTEFb was functional, we performed in vitro kinase assays (IVKA) with the CTD of RNAPII. The CTD of human RNAPII consists of 52 tandem heptapeptide repeats (YSPTSPS). It is thought that P-TEFb targets best serine at position 2 (Zhou et al., 2000; Ramanathan et al., 2001; Kim et al., 2002) . Indeed, anti-P-TEFb and anti-c-Myc immunoprecipitations could phosphorylate 
P-TEFb mediates effects of c-Myc S Kanazawa et al the hybrid GST Á CTD protein equivalently in vitro (Figure 2c , upper panel, lanes 3 and 5). Moreover, this phosphorylation was decreased dramatically when DNCdk9 was coexpressed with HA epitope-tagged CycT1 protein before the immunoprecipitation (Figure 2c , upper panel, compare lanes 3 and 5 to lanes 4 and 6). Also, 5,6-dichloro-1-b-d-ribofuranosylbenzimidazole (DRB), which is a specific inhibitor of Cdk9, abolished this phosphorylation (Figure 2c, lower panel, lanes 3 and 5) . Importantly, at this concentration of DRB, kinase activities of HA epitope-tagged Cdk7 and Cdk8 proteins, which were coexpressed with c-Myc, were not affected (Figure 2c , lower panel, compare lanes 8-11 with lanes 12 and 13). These data indicate that the complex between c-Myc and P-TEFb is functional in vivo.
Next, we wanted to confirm this interaction in a genetic system. It is well known that Tat binds the transactivation response (TAR) RNA and affects only rates of elongation rather than initiation of transcription. A different RNA-tethering assay using the regulator of virion gene expression (Rev) and the stem loop IIB from the Rev response element (RRE) grafted onto the doublestranded stem in TAR performs the same function. Using this system, only P-TEFb and proteins that interact with P-TEFb affect transcription when presented to RNAPII via RNA (Barboric et al., 2001) . Thus, this RNAtethering system represents a genetic assay for the recruitment and activity of P-TEFb on RNAPII. It also renders the activity of the test protein independent of its DNA-binding and other neighboring factors. As presented in Figure 3 , the activity of the Rev.Myc chimera was similar to that of Rev.CycT1 fusion protein in BOSC23 cells (compare lanes 3 and 7). In contrast, the hybrid Rev.Max protein did not activate the target gene, most likely because of low levels of expression of c-Myc in these cells (Figure 1, lanes 1 and 4) . To prove this contention, we coexpressed c-Myc with the Rev.Max chimera. Indeed, cMyc was able to restore up to 50% of the activity of the Rev.Myc chimera in a dose-dependent manner (Figure 3 , compare lanes 5 and 6 to lane 3). Thus, c-Myc and c-Max can associate free of DNA and recruit P-TEFb in cells. These functional studies confirm that c-Myc binds and recruits active P-TEFb complexes to its target transcriptional units in cells.
As P-TEFb is required for its transcriptional effects, it might also play an important role in cellular fates that are dictated by c-Myc. This finding would be analogous to NF-kB, where RelA not only requires P-TEFb for its transcriptional but also for its antiapoptotic effects (Barboric et al., 2001) . To this end, we investigated the ability of inhibitors of P-TEFb to block cellular fates that are dictated by c-Myc. It is well known that c-Myc induces proliferation and apoptosis of cells grown in low serum (Evan et al., 1992) . The apoptotic pathway involves the release of cytochrome c from mitochondria (Juin et al., 1999) . First, we infected the human lung fibroblast MRC5 cell line with retroviruses expressing Myc.ER TAM chimera and immortalized them with the human telomerase reverse transcriptase (hTERT) gene (Greenberg et al., 1999) . In these cells, the administration of 4-hydroxytamoxifen (OHT) activates Myc.ER TAM chimera, which induces proliferation and apoptosis in the absence of serum (Figure 4 , compare panels b and c to panel a). However, when the specific PTEFb inhibitor DRB, which does not itself affect cell viability at these concentrations (Barboric et al., 2001) , was added to these cells, it inhibited both proliferation and apoptosis (Figure 4, panel d) . Importantly, DRB did not block the expression of c-Myc, which was activated from the Myc.ER TAM fusion protein (data not presented). These data are also expressed numerically in the table in Figure 4 . At this concentration of DRB, overall transcription by RNAPII was also not affected ( Figure 4 , panel e, compare graphs with no DRB (black circles) and 20 mm DRB (black squares) to those with 50 mm DRB (black triangles) and a-amantidin (white squares))(Chao and Price, 2001 ). Thus, P-TEFb not only mediates its transcriptional effects, but is also required for cellular fates that are governed by c-Myc.
In this study, we established a direct structural and functional link between c-Myc and P-TEFb. Importantly, our findings connect a CTD kinase and transcriptional elongation with effects of c-Myc in cells. They confirm previous findings with the cad gene, demonstrate the specificity of binding between c-Myc and P-TEFb, show the recruitment of P-TEFb biochemically and genetically and extend the importance of this interaction to cell fates. Thus, inhibiting P-TEFb to block effects of c-Myc in transformed cells offers a new target in cancer therapeutics. Moreover, different onco- 
Materials and methods

CAT assays
BOSC23 cells were cotransfected with plasmid effectors and target using lipofectamine (GIBCO-BRL, Piscataway, NJ, USA). At 24 h after the transfection, cells were harvested, upon which CAT assays and Western blotting were performed (Kanazawa et al., 2000) .
In vitro kinase assays COS cells were cotransfected as above. At 24 h after the transfection, cells were harvested and complexes were immunoprecipitated with the anti-HA or anti-c-Myc antibodies. Immunoprecipitated proteins were mixed with the GST.CTD chimera (100 ng/reaction mixture) in the kinase buffer, 40 mm Tris, pH 7.5, 100 mm KCl, 10 mm MgCl 2 , 10 mm MnCl 2 , 10 mm DTT, 10 mg/ml bovine serum albumin and incubated with g 32 P-ATP at 301C for 30 min in the presence or absence of 20 mm DRB. Phosphorylated proteins were separated on 10% SDS-PAGE and analysed by autoradiography.
Assays for cellular proliferation and apoptosis hTERT and Myc.ER TAM expression vectors were introduced in the human lung fibroblastic MRC5 cells. The expression of the Myc.ER TAM fusion protein was confirmed by Western blotting (data not presented). Cells (2.5 Â 10 5 ) were seeded and cultured in serum-free medium for 48 h. Arrested cells were then treated with 100 mm 4-OHT alone or in combination with DRB (20 mm) for up to 48 h. Cells were harvested at 6, 12, 24 and 48 h and fixed in 70% ethanol for at least 15 min at 41C and stained with 50 mg/ml propidium iodide for 30 min. FACS analyses were performed by FACScan and analysed by Modifit (Becton Dickinson).
Nuclear run-on assays
In all, 2.5 Â 10 5 MRC5 cells/ml were untreated or treated with different concentrations of DRB for 1 h. Several batches of 10 7 nuclei were isolated from 500 ml of cells and incubated in 0.12 m KCl, 7 mm Mg(Ac) 2 , 25 mCi of [ 32 P]GTP, 500 mm ATP, GTP and CTP with or without 2 mg/ml a-amantidine, as described previously (Chao and Price, 2001) . Duplicate reactions were stopped at indicated time points with a solution of 1% sarkosyl, 0.1 m Tris, pH 8.0, 0.1 m NaCl, 10 mm EDTA and 200 mg/ml tRNA. Stopped reactions were transferred to Whatman DE81 paper and the paper was washed four times with a solution of 5% K 2 HPO 4 and .3% Na 4 P 2 O 7 , then with water and dried after the last wash with 95% EtOH. Counts were quantitated using a liquid scintillation counter (BioRad, Hercules, CA, USA). 
